Takeda Pharmaceutical Co Ltd: Q3 FY2024 Earnings Summary
Business Context and Reporting Period
This Form 6-K filing reports the consolidated financial results for Takeda Pharmaceutical Company Limited for the nine-month period ended December 31, 2024 (April 1, 2024 to December 31, 2024). The report was issued on January 30, 2025. Takeda operates as a single operating segment focused on the research, development, manufacturing, and marketing of pharmaceutical products across six key business areas: Gastroenterology (GI), Rare Diseases, Plasma-Derived Therapies (PDT), Oncology, Vaccines, and Neuroscience.
Key Financial Metrics
| Metric | 9 Months Ended Dec 31, 2024 | 9 Months Ended Dec 31, 2023 | Change (AER) |
|---|---|---|---|
| Revenue | JPY 3,528.2 billion | JPY 3,212.9 billion | +9.8% |
| Operating Profit | JPY 417.5 billion | JPY 224.1 billion | +86.3% |
| Profit Before Tax | JPY 282.4 billion | JPY 100.3 billion | +181.5% |
| Net Profit (Attributable to Owners) | JPY 211.1 billion | JPY 147.1 billion | +43.5% |
| Basic EPS | JPY 133.71 | JPY 94.10 | +42.1% |
| Core Operating Profit | JPY 1,006.3 billion | JPY 865.6 billion | +16.3% |
| Core EPS | JPY 443 | JPY 412 | +7.5% |
| Total Assets | JPY 15,106.8 billion | JPY 15,108.8 billion | -0.01% |
| Total Equity | JPY 7,419.2 billion | JPY 7,274.0 billion | +2.0% |
| Cash & Equivalents | JPY 494.1 billion | JPY 288.4 billion | +71.3% |
| Operating Cash Flow | JPY 835.0 billion | JPY 437.8 billion | +90.7% |
Material Changes vs. Prior Period
- Revenue Growth: Driven by favorable foreign exchange rates and strong performance in GI (ENTYVIO), Rare Diseases (TAKHZYRO, LIVTENCITY), PDT (immunoglobulins), Oncology (FRUZAQLA, ADCETRIS), and Vaccines (QDENGA). Growth was partially offset by declines in Neuroscience due to generic erosion of VYVANSE in the U.S. and AZILVA in Japan.
- Profitability Surge: Operating profit increased significantly (86.3%) due to revenue growth, reduced R&D expenses (termination of programs like modakafusp alfa and EXKIVITY), and lower impairment losses compared to the prior year. The prior year included significant impairment charges for ALOFISEL and EXKIVITY.
- Cost Management: R&D expenses decreased by 3.7% (AER) and SG&A expenses increased by 5.2% (AER), primarily due to the depreciation of the Japanese yen.
- Balance Sheet: Total liabilities decreased by JPY 147.1 billion, driven by payments to suppliers and amortization of deferred tax liabilities. Total bonds and loans stood at JPY 4,840.1 billion.
Guidance, Outlook, and Risks
Revised Full-Year Forecast (FY Ending March 31, 2025): Takeda has revised its full-year forecasts upward from the October 2024 announcement.
- Revenue: Revised to JPY 4,590.0 billion (Previous: JPY 4,480.0 billion). Increase driven by slower-than-anticipated generic erosion of VYVANSE and favorable FX assumptions.
- Operating Profit: Revised to JPY 344.0 billion (Previous: JPY 265.0 billion). Increase reflects VYVANSE performance and R&D savings, partially offset by a one-time inventory accounting adjustment of JPY 29.9 billion.
- Net Profit: Revised to JPY 118.0 billion (Previous: JPY 68.0 billion).
- Core EPS: Revised to JPY 507 (Previous: JPY 456).
Management Guidance (Constant Exchange Rate):
- Core Revenue: Low-single-digit % increase (Revised from "Flat to slightly increasing").
- Core Operating Profit: Low-single-digit % increase (Revised from "Mid-single-digit % decline").
- Core EPS: Flat to slightly declining (Revised from "Approx 10% decline").
Risks and Contingencies:
- Product Liability: Over 6,100 lawsuits regarding PREVACID and DEXILANT (kidney injury/gastric cancer claims) were pending. Takeda reached a settlement agreement in principle in April 2024 and executed a final agreement in November 2024. The settlement amount is non-material and has no material impact on the current period's results.
- Generic Erosion: Continued pressure on VYVANSE (Neuroscience) and AZILVA (Other) due to generic competition.
- FX Volatility: Results are sensitive to fluctuations in foreign exchange rates, particularly the USD/JPY and EUR/JPY.
Key Facts for Investor Verification
- Share Repurchase Program: On January 30, 2025, the Board resolved to repurchase up to 28.5 million shares (approx. 1.8% of outstanding shares) for up to JPY 100 billion between February 17, 2025, and May 31, 2025.
- Dividend Projection: Total annual dividend projected at JPY 196.00 per share for FY2025 (up from JPY 188.00 in FY2024).
- Inventory Accounting Adjustment: Verify the impact of the JPY 29.9 billion one-time adjustment to cost of sales related to accumulated foreign currency impacts on inventories, which reduced the operating profit forecast.
- Debt Structure: Note the recent refinancing activities, including the issuance of JPY 460 billion in 60-year hybrid bonds and USD 3 billion in senior notes to redeem older debt and reduce commercial paper.
- Non-IFRS Measures: Investors should review the "Definition and Explanation of Non-IFRS Measures" in the Financial Appendix to understand the reconciliation between IFRS and Core financial measures.